Medical Xpress

Extended RAS testing urged before EGFR MoAB therapy

(HealthDay)—For patients with metastatic colorectal cancer, anti-epidermal growth factor receptor (EGFR) monoclonal antibody (MoAB) therapy should be considered only after extended RAS testing, ...
Medscape

Mandatory Extended RAS Testing for mCRC

Extended RAS Mutations and Anti-EGFR Monoclonal Antibody Survival Benefit in Metastatic Colorectal Cancer: a Meta-analysis of Randomized Controlled Trials This study confirms emerging data from a ...
ascopubs.org

Controlling the quality of RAS mutation testing by a dichotomous approach: Ring trials and benchmarking mutation frequencies by a RAS monitor.

Quality-adjusted survival in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) receiving first-line therapy with panitumumab plus FOLFOX versus FOLFOX alone in the PRIME trial. This ...
Business Insider

Sysmex Inostics' OncoBEAMTM RAS CRC testing supports clinical outcome improvements for metastatic colorectal cancer patients rechallenged with anti-EGFR therapy

BALTIMORE, Aug. 27, 2020 /PRNewswire/ -- Sysmex Inostics, Inc., a global leader and pioneer in blood-based circulating tumor DNA (ctDNA) analysis for oncology, today announces the publication of a ...
ascopubs.org

Evolution of RAS testing in colorectal cancer in France, Germany, Italy, Spain and UK (EU5).

Cetuximab plus chemotherapy as second line treatment of patient with metastatic colorectal cancer after failure of cetuximab containing regiment in first line: Single cancer center experience. This is ...
The American Journal of Managed Care

FDA Approves RAS Mutation Detection Kit as Companion Diagnostic for Panitumumab in mCRC

The FDA has approved the CRCdx RAS Mutation Detection Kit as a companion diagnostic for panitumumab in the treatment of patients with metastatic colorectal cancer (mCRC), according to an announcement ...
Business Insider

Sysmex-Inostics Colorectal Cancer Blood-Based OncoBEAMTM RAS CE-IVD Test Shows Concordance with Standard of Care Tissue-Based RAS Testing

BALTIMORE, Aug. 5, 2020 /PRNewswire/ -- Sysmex-Inostics, Inc., a global leader and pioneer in blood-based circulating tumor DNA (ctDNA) analysis for oncology, today announces the publication of a ...
technologynetworks

New Liquid Biopsy RAS Testing Available for Clinical Practices

Sysmex Inostics has announced that its OncoBEAM® RAS CRC test has been granted CE Mark approval. The test, developed by Sysmex Inostics GmbH in collaboration with Merck, can now be accessed by ...